文献速递膀胱癌与上尿路尿路上皮癌

无选择法表征尿路上皮癌循环肿瘤细胞

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
PubMed 文献 · Urology · 2018-02-09

研究采用无选择法(AccuCyte-CyteFinder系统)检测38例不同分期尿路上皮癌患者及对照的循环肿瘤细胞(CTC),发现CTC在各期均可检出且具有细胞大小和EpCAM表达异质性,部分EpCAM阴性CTC会被CellSearch漏检。

要点

  • 无选择法在NMIBC、MIBC和转移性UC中分别检出25%、58%和67%的CTC。
  • 以EpCAM阳性为CTC标准时,NMIBC中无CTC检出,MIBC仅17%检出。
  • 转移性患者CTC倾向于更大,且仅对照组与转移性UC的CTC计数差异有统计学意义。

核心结论

  • CTC在尿路上皮癌各期均可检出,并呈现细胞大小和EpCAM表达的异质性。
  • 无选择法可检出NMIBC和MIBC患者中EpCAM阴性、CellSearch会漏检的CTC。

研究设计与样本

  • 研究纳入38例受试者,包括9例对照、8例非肌层浸润性膀胱癌(NMIBC)、12例肌层浸润性膀胱癌(MIBC)和9例转移性尿路上皮癌(UC)。
  • 血样采用AccuCyte-CyteFinder系统处理,玻片染色CD45、CD66b、EpCAM和pancytokeratin。
  • CTC定义为细胞角蛋白阳性且白细胞标志物阴性的细胞,另按CellSearch定义附加EpCAM阳性要求。
  • 采用Kruskal-Wallis ANOVA检验比较各分期间CTC计数。

主要发现

  • NMIBC患者中2/8(25%)检出≥1个CTC。
  • MIBC患者中7/12(58%)检出≥1个CTC。
  • 转移性UC患者中6/9(67%)检出≥1个CTC。
  • 对照组均未检出CTC。
  • 仅对照组与转移性UC组间CTC计数差异有统计学意义(P = .009)。

临床怎么用

  • 无选择法可提高NMIBC和MIBC中CTC检出率,尤其可捕获EpCAM阴性CTC。
  • CellSearch依赖EpCAM阳性选择,在NMIBC中可能漏检CTC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate circulating tumor cells (CTCs) as biomarkers of urothelial carcinoma (UC). To date, the majority of work on this topic has utilized the CellSearch test, which has limited sensitivity due to reliance on positive selection for the cell surface protein epithelial cell adhesion molecule (EpCAM). We used a novel selection-free method to enumerate and characterize CTCs across a range of UC stages. MATERIALS AND METHODS: Blood samples from 38 patients (9 controls, 8 nonmuscle invasive bladder cancer [NMIBC], 12 muscle-invasive bladder cancer [MIBC], and 9 metastatic UC) were processed with the AccuCyte-CyteFinder system. Slides were stained for the white blood cell markers CD45 and CD66b and the epithelial markers EpCAM and pancytokeratin. CTCs were defined as any cytokeratin postive and white blood cell marker negative cell. Separately, the more restrictive CellSearch definition was applied, with the additional requirement of EpCAM positivity. The Kruskal-Wallis ANOVA test compared CTC counts by stage. RESULTS: Greater than or equal to 1 CTC was detected in 2 of 8 (25%) patients with NMIBC, 7 of 12 (58%) with MIBC, and 6of 9 (67%) with metastatic disease. No control had CTCs. Comparing CTC counts between groups, the only statistically significant comparison was between controls and patients with metastatic UC (P = .009). With EpCAM positivity as a CTC requirement, no CTCs were detected in any patient with NMIBC, and only 2 (17%) patients with MIBC had CTCs. CTCs tended to be larger in metastatic patients. CONCLUSION: CTCs were detected at all UC stages and exhibited phenotypic diversity of cell size and EpCAM expression. EpCAM negative CTCs that would be missed with the CellSearch test were detected in patients with NMIBC and patients with MIBC.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chalfin HJ, Kates M, van der Toom EE, et al. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. Urology. 2018. PMID: 29432873. doi:10.1016/j.urology.2018.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。